C4 Therapeutics (CCCC) EPS (Weighted Average and Diluted) (2021 - 2025)
Historic EPS (Weighted Average and Diluted) for C4 Therapeutics (CCCC) over the last 5 years, with Q3 2025 value amounting to -$0.44.
- C4 Therapeutics' EPS (Weighted Average and Diluted) fell 2571.43% to -$0.44 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.44, marking a year-over-year decrease of 2571.43%. This contributed to the annual value of -$1.52 for FY2024, which is 4307.12% up from last year.
- Per C4 Therapeutics' latest filing, its EPS (Weighted Average and Diluted) stood at -$0.44 for Q3 2025, which was down 2571.43% from -$0.37 recorded in Q2 2025.
- C4 Therapeutics' EPS (Weighted Average and Diluted)'s 5-year high stood at -$0.26 during Q2 2024, with a 5-year trough of -$0.76 in Q4 2022.
- For the 5-year period, C4 Therapeutics' EPS (Weighted Average and Diluted) averaged around -$0.52, with its median value being -$0.51 (2021).
- As far as peak fluctuations go, C4 Therapeutics' EPS (Weighted Average and Diluted) plummeted by 14516.13% in 2022, and later surged by 6438.36% in 2024.
- Quarter analysis of 5 years shows C4 Therapeutics' EPS (Weighted Average and Diluted) stood at -$0.31 in 2021, then tumbled by 145.16% to -$0.76 in 2022, then rose by 10.53% to -$0.68 in 2023, then rose by 27.94% to -$0.49 in 2024, then rose by 10.2% to -$0.44 in 2025.
- Its EPS (Weighted Average and Diluted) stands at -$0.44 for Q3 2025, versus -$0.37 for Q2 2025 and -$0.37 for Q1 2025.